Clinical trial
Double Blind, Randomized Phase III Study to Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children
NCT04618939 is registered in ClinicalTrials.gov with Boryung Biopharma Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Double Blind, Randomized Phase III Study to Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children
- Lead sponsor
- Boryung Biopharma Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 20, 2016
- Completion date
- April 28, 2017
- Enrollment
- 218 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.